Advocating for Psycho-Social Oncology Care

News
Video

Sally Werner, RN, BSN, MSHA, discusses the crucial role of psycho-social oncology in cancer care, including how clinicians and administrators can advocate for these vital services.

In the complex landscape of oncology, where the focus is often on clinical outcomes and cost-effectiveness, the essential role of psycho-social oncology can sometimes be overlooked. Yet, as Sally Werner, RN, BSN, MSHA, chief executive officer of Cancer Support Community, emphasized, these supportive services are more than just a complement to care; they are a fundamental component of a patient’s journey through a cancer diagnosis.

As an oncology nurse, Werner has a unique perspective on the critical marriage of clinical and supportive care. She understands the challenges clinicians and administrators face when trying to justify the budget for these services. However, she argues that the data is clear: investing in psycho-social care directly improves patient outcomes. Whether it's enhancing adherence to treatment or addressing the practical, logistical burdens faced by patients and their families, these services ease the burden of treatment and allow patients to be more engaged in their own care.

Transcript:

Psychosocial oncology is half, if not more, of making it through a cancer diagnosis. I’m an oncology nurse by background; even though I work with 650 plus social workers, I think that this marriage [between] clinical care and supportive care is so critical. It’s hard to make that case sometimes in the budget for bringing in those support services, but honestly, there’s enough data out today to prove that outcomes can be improved when there are those support services in place. Whether that’s adherence to care [or] understanding some of the practical, logistical concerns of patients and family members, it eases the burden and doesn’t put all of that on the patient and on their caregiver; we can ease that for them and take a lot of that off [their shoulders]. When I’m justifying being in partnership with a cancer support community or another advocacy organization, [where] some of the dollars attached to that [will go], oftentimes those types of partnerships cost far less than 1 full-time employee. You have a whole program to offer patients, caregivers, and the community at large, for less than the cost of a full-time employee with benefits. The financial model exists today where it’s sometimes what we do that is subsidized by some billing codes, but for the most part, a good portion of what we do is not fully subsidized. It’s making that case of patient outcomes and easing their burden so that they can be strong advocates and partners and engaged in their own care.

Recent Videos
Reducing the manufacturing time of CAR T-cell therapy may have a big impact on the treatment of patients with mantle cell lymphoma.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
Related Content